- Home
- CVRX vs KZIA Comparison
CVRX vs KZIA Comparison
Compare CVRX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVRX | KZIA |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 154.5M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CVRX | KZIA |
|---|---|---|
| Price | $3.37 | $13.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $10.50 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.4M | 182.9K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,651,000.00 | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $2.20 | $4.86 |
| 52 Week High | $11.30 | $17.40 |
Technical Indicators
Market Signals| Indicator | CVRX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 50.33 |
| Support Level | $2.20 | $11.39 |
| Resistance Level | $3.24 | $14.75 |
| Average True Range (ATR) | 0.30 | 0.96 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 26.32 | 46.77 |
Price Performance
Historical ComparisonAbout CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.